Wytyczne kardiodiabetologiczne w praktyce lekarza rodzinnego

• Authors: Pupek-Musialik Danuta , Musialik Katarzyna
• Languages of publication: PL

Keywords

PL

cukrzyca; powikłania sercowo-naczyniowe; profilaktyka

• Publisher: Stowarzyszenie Przyjaciół Medycyny Rodzinnej i Lekarzy Rodzinnych
• Journal: Family Medicine & Primary Care Review
• Year: 2012
• Issue: 3
• Pages: 489-496

Contributors

author

Pupek-Musialik Danuta

author

Musialik Katarzyna

References

• Tatoń J, Czech A. Podręcznik opieki angiometabolicznej oparty na patofizjologii i EBM. Przegl Kardiodiab 2011,1−2(6): 1–211.
• Tatoń J, Czech A, Krzemińska-Pakuła M, i wsp. Rekomendacje prewencji, diagnostyki i leczenia chorób układu sercowo-naczyniowego u osób z cukrzycą. Polskie Towarzystwo Kardiodiabetologiczne 2009/2009. Przegl Kardiodiab 2008.2(3): 1−207.
• Kinalska I, Pupek-Musialik D, red. Problemy kardiologiczne w cukrzycy. Poznań: Wydawnictwo Termedia; 2008.
• American Diabetes Association. Standards of medical care 2010. Diab Care 2010; 33(Suppl. 1).
• European Arterial Risk Policy Group on behalf on the International Diabetes Federation (European Region). A strategy for arteria risk assessment and management in type 2 (non-insulin-dependent) diabetes. Diabet Med 1997; 14: 611.
• Ihnsook J, Myunghee K, Jungsoon K. Predictive accuracy of severity scoring system: a prospective cohort study Rusing APACHE III in a Korean intensiva care unit. Int J Nurs Stud 2003; 40(3): 219−226.
• Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2010. Stanowisko Polskiego Towarzystwa Diabetologicznego. Diabetol Prakt 2011; 11−50(Supl. A).
• American Diabetes Association. Standards of Medical Care in Diabetes 2011. Diab Care 2011; 343(Suppl. 1):340−370.
• The DECODE Study Group. Gender difference in all-cause and cardiovascular mortality related to hyperglycemia and newly diagnosed diabetes. Diabetologia 2003; 46: 608−617.
• Stratton IM, Adler AL, Neil HA, et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): a prospective observational study. BMJ 2000; 321: 405−512.
• UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonyloureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837−853.
• Patel AADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829−840.
• The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensiva glucose lowering in type 2 diabetes. New Engl J Med 2008; 358: 2545−2559.
• Duckworth W, Abraira C, Moritz T, et al. for the VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129−139.
• Gillen JB, Little JP, Punthakee Z, et al. Acute high-intensity interwal exercise reduces the postprandial glucose response and prevalence of hyperglycemia in patients with type 2 diabetes. Diab Obes Metab 2012; Jan 23. Doi:10.1111/j.1463-1326.2012.01564.
• Buse JB, Freeman JLR, Edelman SV, et al. Serum 1,5-anhydroglucitol (GlycoMakTM): a short-term glycemic marker.Diabetes Technol Ther 2003; 5: 355−363.
• Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensiva diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995; 75:894−903.
• Diabetes Control and Complications Trial: Epidemiology of Diabetes Interventions and Complications (DCCT-EDIC) Study Research Group. National Diabetes Information Clearinghouse (NDIC). National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. 2008-05. Archived from the original on 2007-10-18.http://web.archive.org/web/20071018034602/http://diabetes.niddk.nih.gov/dm/pubs/control/. Retrieved 2010-06-10.
• Collins R, Armitage J, Parish S, et al. Heart protection Study Collaborative Group. MRC/BHF. Heart Protection Study of cholesterol-lowering with simwastatin in 5963 people with diabetes a randomized placebo-controlled trial. Lancet 2003; 361: 2005−2016.
• Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trias of statins: a meta-analysis. Lancet 2006; 371: 117−125.
• Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet 2005; 366: 1849−1861.
• Kastelein JJ, Akdim F, Stroes ES, et al. ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hipercholesterolemia.N Engl J Med 2008; 358: 1431−1443.
• Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertensin management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121−2158.
• Pasi KJ, Enayat MS, Horrocks PM, et al. Qualitative and quantitative abnormalities of von Willebrand antygen in patients with diabetes mellitus. Thromb Res 1990; 59: 581−591.
• Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC; National Heart, Lung and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and Rother atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung and Blood Institute. Circulation 2006; 113: 2363−2372.
• Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arteria disease in the CHARISMA trial. J Am Coll Cardiol 2007; 49: 1982−1988
• Biondi-Zoccai GG, Abbate A, Liuzzo G, et al. Atherothrombosis, inflammation and diabetes. J Am Coll Cardiol 2003;41: 1071−1077
• Duncan BB, Schmidt MI, Pankow JS, et al. Low-grade systemie inflammationand the development of type 2 diabetes:the Atherosclerosis Risk in Communities Study. Diabetes 2003; 52: 1799−1805.
• Sattar N. High sensitive C-reactive protein in cardiovascular disease and diabetes: evidence for a clinical role? Br J Diab Vasc Dis 2006; 6: 5−8.
• Carter AM, Bennett LE, Bostock JA, et al. Metformin reduces C-reactive protein but not komplement factor C3 in overweight patients with type 2 diabetes mellitus. Diab Med 2005; 22: 1282−1284